Engineered CH2 domains (nanoantibodies)
- 1 January 2009
- journal article
- review article
- Published by Taylor & Francis in mAbs
- Vol. 1 (1) , 26-28
Abstract
Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size antibodies mostly in IgG1 format of about 150 kDa size. A fundamental problem for such large molecules is their poor penetration into tissues (e.g., solid tumors) and poor or absent binding to regions on the surface of some molecules (e.g., on the HIV envelope glycoprotein) which are fully accessible only by molecules of smaller size. Therefore, much work especially during the last decade has been aimed at developing novel scaffolds of much smaller size and high stability. Here I briefly describe a proposition to use the immunoglobulin (Ig) constant CH2 domain (CH3 for IgE and IgM) as a scaffold. CH2 is critical for the Ig effector functions. Isolated CH2 is stable monomer in contrast to all other constant domains and most of the variable domains. CH2 and engineered CH2 domains with improved stability can be used as scaffolds for con...Keywords
This publication has 14 references indexed in Scilit:
- Dynamics of Antibody Domains Studied by Solution NMR2008
- Construction of a Large Phage-Displayed Human Antibody Domain Library with a Scaffold Based On a Newly Identified Highly Soluble, Stable Heavy Chain Variable DomainJournal of Molecular Biology, 2008
- Alternative binding proteins get mature: Rivalling antibodiesThe FEBS Journal, 2008
- Alternative non-antibody scaffolds for molecular recognitionCurrent Opinion in Biotechnology, 2007
- Artificial, non-antibody binding proteins for pharmaceutical and industrial applicationsTrends in Biotechnology, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Folding Mechanism of the CH2 Antibody DomainJournal of Molecular Biology, 2004
- Binding proteins from alternative scaffoldsJournal of Immunological Methods, 2004
- Domain antibodies: proteins for therapyTrends in Biotechnology, 2003
- Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc ComplexMolecular Cell, 2001